DK1147114T3 - Hidtil ukendt aralkylaminer af spirofuropyridiner, der er egnede til terapi - Google Patents

Hidtil ukendt aralkylaminer af spirofuropyridiner, der er egnede til terapi

Info

Publication number
DK1147114T3
DK1147114T3 DK99967044T DK99967044T DK1147114T3 DK 1147114 T3 DK1147114 T3 DK 1147114T3 DK 99967044 T DK99967044 T DK 99967044T DK 99967044 T DK99967044 T DK 99967044T DK 1147114 T3 DK1147114 T3 DK 1147114T3
Authority
DK
Denmark
Prior art keywords
spirofuropyridines
aralkylamines
therapy
new
spirofuropyridines suitable
Prior art date
Application number
DK99967044T
Other languages
English (en)
Inventor
Eifion Phillips
James Loch Iii
George Mullen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1147114T3 publication Critical patent/DK1147114T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK99967044T 1999-01-15 1999-12-23 Hidtil ukendt aralkylaminer af spirofuropyridiner, der er egnede til terapi DK1147114T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9900100A SE9900100D0 (sv) 1999-01-15 1999-01-15 New compounds
PCT/SE1999/002478 WO2000042044A1 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy

Publications (1)

Publication Number Publication Date
DK1147114T3 true DK1147114T3 (da) 2003-09-15

Family

ID=20414101

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99967044T DK1147114T3 (da) 1999-01-15 1999-12-23 Hidtil ukendt aralkylaminer af spirofuropyridiner, der er egnede til terapi

Country Status (34)

Country Link
US (2) US6995167B2 (da)
EP (1) EP1147114B1 (da)
JP (1) JP2002534525A (da)
KR (1) KR100660496B1 (da)
CN (1) CN1132837C (da)
AR (1) AR022283A1 (da)
AT (1) ATE240960T1 (da)
AU (1) AU775433B2 (da)
BR (1) BR9916906A (da)
CA (1) CA2359990A1 (da)
CZ (1) CZ20012554A3 (da)
DE (1) DE69908185T2 (da)
DK (1) DK1147114T3 (da)
EE (1) EE04528B1 (da)
ES (1) ES2200590T3 (da)
HK (1) HK1040517B (da)
HU (1) HUP0200513A3 (da)
ID (1) ID30034A (da)
IL (1) IL144266A0 (da)
IS (1) IS6000A (da)
MY (1) MY118109A (da)
NO (1) NO20013478L (da)
NZ (1) NZ512733A (da)
PT (1) PT1147114E (da)
RU (1) RU2233282C2 (da)
SA (1) SA00200987B1 (da)
SE (1) SE9900100D0 (da)
SI (1) SI1147114T1 (da)
SK (1) SK9932001A3 (da)
TR (1) TR200102042T2 (da)
TW (2) TW200413387A (da)
UA (1) UA71598C2 (da)
WO (1) WO2000042044A1 (da)
ZA (1) ZA200105527B (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
ATE353332T1 (de) * 2001-06-01 2007-02-15 Astrazeneca Ab Neuer, für die therapie geeigneter ligand für nikotinische acetylcholinrezeptoren
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
IL160884A0 (en) * 2001-10-02 2004-08-31 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
WO2003087103A1 (en) 2002-04-18 2003-10-23 Astrazeneca Ab Thienyl compounds
US7417049B2 (en) * 2002-04-18 2008-08-26 Astrazeneca Ab Furyl compounds
CA2482313A1 (en) * 2002-04-18 2003-10-23 Astrazeneca Ab Heterocyclic compounds
EP1531820A1 (en) 2002-08-30 2005-05-25 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
EP2062595A1 (en) * 2002-12-06 2009-05-27 The Feinstein Institute for Medical Research Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
JP4598674B2 (ja) * 2003-01-08 2010-12-15 田辺三菱製薬株式会社 統合失調症治療剤
US20050129610A1 (en) * 2003-06-24 2005-06-16 Johns Hopkins University Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor
BRPI0415546A (pt) * 2003-10-21 2006-12-26 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
AU2005227324A1 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
RU2448111C2 (ru) * 2006-08-21 2012-04-20 Дженентек, Инк. Соединения азабензофуранила и способ их применения
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
NZ590616A (en) 2008-06-20 2012-09-28 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
EP2942350A1 (en) 2008-10-17 2015-11-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
PL2540297T3 (pl) 2008-11-19 2015-12-31 Forum Pharmaceuticals Inc Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
RU2015103694A (ru) 2009-10-14 2015-06-27 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
PL3029039T3 (pl) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CN105753877A (zh) 2012-04-12 2016-07-13 泽农医药公司 用作治疗剂的螺-羟吲哚化合物的不对称合成
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
WO2014202999A1 (en) 2013-06-21 2014-12-24 Takeda Cambridge Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311313B1 (en) * 1987-10-05 1995-05-10 Yamanouchi Pharmaceutical Co. Ltd. Heterocyclic spiro compounds and their preparation
JPH0195922A (ja) 1987-10-08 1989-04-14 Mazda Motor Corp 車両のサスペンション制御装置
JP3708962B2 (ja) * 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
JP4176147B2 (ja) 1995-07-28 2008-11-05 アボツト・ラボラトリーズ 化学的シナプス伝達の制御に有用なフロピリジン、チエノピリジン、ピロロピリジンおよび関連するピリミジン、ピリダジンおよびトリアジン化合物
US6156783A (en) 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
US6995167B2 (en) 2006-02-07
HK1040517B (zh) 2003-09-05
AU775433B2 (en) 2004-07-29
KR20010086167A (ko) 2001-09-08
WO2000042044A1 (en) 2000-07-20
PT1147114E (pt) 2003-10-31
NZ512733A (en) 2003-08-29
AR022283A1 (es) 2002-09-04
US20030149065A1 (en) 2003-08-07
NO20013478D0 (no) 2001-07-13
ES2200590T3 (es) 2004-03-01
EE200100370A (et) 2002-10-15
JP2002534525A (ja) 2002-10-15
SK9932001A3 (en) 2002-04-04
ATE240960T1 (de) 2003-06-15
DE69908185D1 (de) 2003-06-26
US7196096B2 (en) 2007-03-27
ID30034A (id) 2001-11-01
BR9916906A (pt) 2001-10-30
AU2334300A (en) 2000-08-01
US20050250802A1 (en) 2005-11-10
HUP0200513A2 (en) 2002-06-29
DE69908185T2 (de) 2004-06-03
EE04528B1 (et) 2005-08-15
IS6000A (is) 2001-07-12
TR200102042T2 (tr) 2002-05-21
ZA200105527B (en) 2002-10-04
SA00200987B1 (ar) 2006-11-07
TW200413387A (en) 2004-08-01
CA2359990A1 (en) 2000-07-20
NO20013478L (no) 2001-09-14
EP1147114B1 (en) 2003-05-21
MY118109A (en) 2004-08-30
EP1147114A1 (en) 2001-10-24
RU2233282C2 (ru) 2004-07-27
SI1147114T1 (en) 2003-12-31
CN1337964A (zh) 2002-02-27
IL144266A0 (en) 2002-05-23
TWI227237B (en) 2005-02-01
HUP0200513A3 (en) 2004-07-28
CZ20012554A3 (cs) 2002-01-16
SE9900100D0 (sv) 1999-01-15
HK1040517A1 (en) 2002-06-14
CN1132837C (zh) 2003-12-31
UA71598C2 (en) 2004-12-15
KR100660496B1 (ko) 2006-12-22

Similar Documents

Publication Publication Date Title
DK1147114T3 (da) Hidtil ukendt aralkylaminer af spirofuropyridiner, der er egnede til terapi
DK1386921T3 (da) Mellemprodukter til fremstilling af anti-trombotiske 4H-cycolopenta-1,3-dioxol-derivater
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1173431T3 (da) Fremgangsmåde til fremstilling af citalopram
EE200200183A (et) Meetod polüisobuteenfenooli sisaldavate Mannichi aduktide saamiseks
DK1105382T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1159274T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1459749T3 (da) (S,S)-reboxetin til behandling af inkontinens
EE200200082A (et) Uued spiroühendid
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DK0944631T3 (da) Nye substituerede pyrazolderivater til behandling af hjertekredslöbssygdomme
DK1176195T3 (da) Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1165576T3 (da) Fremgangsmåde til fremstilling af amin-platin-komplekser
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK0912537T3 (da) Fremgangsmåde til fremstilling af phenylheterocykliske forbindelser, der er anvendelige som cox-2-inhibitorer
DK1200081T3 (da) Anvendelse af escitalopram til behandling af generaliseret angstlidelse
DK0983275T3 (da) Nye triptolidderivater, der er nyttige til behandling af autoimmune sygdomme
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
DK1298124T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater
DK1148874T3 (da) Anvendelse af antikonvulsive derivater til behandling af bulimia nervosa
DK1341758T3 (da) Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme